What happened with INSP today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Inspire Medical Systems treats moderate-to-severe obstructive sleep apnea, in which the airway becomes blocked during sleep. Its implanted Inspire system monitors breathing and stimulates the nerve controlling the tongue as the patient inhales, moving the tongue forward to help keep the airway open. In the United States, the therapy is approved only for patients who have failed or cannot tolerate positive airway pressure treatment, such as CPAP.
Hospitals and outpatient surgery centers buy the system and bill insurers, government healthcare programs and patients for treatment. Nearly all company revenue comes from Inspire system sales, overwhelmingly in the United States. The company also sells directly in selected European countries and Japan and uses distributors in certain Asian markets.
Sales depend on physicians recommending the therapy, patients accepting an implant and facilities receiving adequate reimbursement. Coverage rules and prior authorization affect access, while the device’s cost can reduce a facility’s margin. Coding and reimbursement for Inspire V remain unsettled, affecting what providers are paid and their willingness to perform procedures.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Inspire's growth also depends on reimbursement, surgical capacity and patients' choice of alternatives, including PAP devices from Philips and Fisher & Paykel and GLP-1 drugs such as Zepbound.
Nyxoah SA competes directly with Inspire for moderate-to-severe obstructive sleep apnea patients: its Genio implant also stimulates the nerve controlling the tongue to keep the airway open, with overlapping treatment indications and active patent disputes. Genio's U.S. sales, which began in September 2025, show how its commercial rollout is progressing against Inspire.
ResMed treats patients before they become candidates for Inspire: it sells first-line devices that deliver pressurized air through a mask, known as CPAP, to healthcare providers and patients, while Inspire's U.S. implant is limited to patients who fail or cannot tolerate positive airway pressure treatment. Watch continued CPAP prescribing even when patients use it poorly, which can keep them on that treatment rather than moving to Inspire.
LivaNova PLC's aura6000 program could add another rival to Inspire by treating obstructive sleep apnea through stimulation of the nerve controlling the tongue. Its 2025 FDA application to market the device in the U.S. makes regulatory progress on aura6000 the news to watch, rather than sales of LivaNova's heart-lung machines or its nerve-stimulation devices for epilepsy and depression.
Apnimed, Inc. could give adults with obstructive sleep apnea an oral-drug alternative to Inspire's implanted treatment, but its Oxnimbi (AD109) candidate is not yet approved or generating product sales. The FDA accepted its application in July 2026 and set February 28, 2027 as the target decision date—the next concrete milestone for this potential rival.
Vivos Therapeutics, Inc. offers patients oral appliances instead of Inspire's implanted treatment, reaching them through a dental-led channel while Inspire sells systems to hospitals and ambulatory surgery centers. Watch Vivos's appliance sales and its expansion through acquired or managed sleep practices for signs of uptake of this alternative treatment route.
ResMed Inc. earningsRMD
ResMed sells CPAP devices that deliver air through a mask, and its report will show whether demand for this first-line treatment remains strong enough to keep some patients from moving on to Inspire’s implant.
Look at ResMed’s account of CPAP demand and whether the report discusses patients continuing treatment. Strong demand, with patients staying on CPAP even when their use is limited, would suggest that some potential Inspire patients may not move on to an implant. Weaker demand could leave more room for alternatives, but does not establish that patients qualify for or will choose Inspire. The conclusion is whether the first-line CPAP pathway may still be holding back the pool of patients who move to Inspire.
Inspire Medical Systems, Inc. earningsThis company
Inspire Medical Systems mainly sells its implant system to hospitals and surgery centers, and this report will show whether physician and patient adoption is turning into more sales without weakening gross margin.
Read U.S. system-sales growth alongside gross margin. Faster sales with a steady or rising margin would show that physician and patient adoption is turning into shipments, while Inspire V’s lower manufacturing cost is helping preserve the economics of each sale. Slower sales with a falling margin would point to adoption constraints or product and inventory costs offsetting growth. The conclusion is whether demand is becoming more profitable system sales.
Nyxoah SA earningsNYXH
Nyxoah SA also treats obstructive sleep apnea with an implant that stimulates the nerve controlling the tongue, and its report will show how Genio’s U.S. rollout is progressing against Inspire’s direct competition.
Look at Nyxoah’s account of Genio’s U.S. sales and rollout alongside Inspire’s own system sales; the companies’ reporting periods and measures may differ, so the figures are not a direct market-share comparison. Faster Genio sales and rollout would show that another implant is reaching patients and clinicians and could draw from Inspire’s potential demand. Slow progress would show that this rival has yet to demonstrate similar commercial traction. The conclusion is whether Genio is becoming a practical U.S. competitor for Inspire.
